A phase 1/2 dose-finding, safety, and activity study of cabazitaxel in pediatric patients with refractory solid tumors including tumors of the central nervous system.
Manley PE, Trippett T, Smith AA, Macy ME, Leary SES, Boklan J, Cohen KJ, Goldman S, Kilburn LB, Dhall G, Devin J, Herzog CE, Partap S, Fauchet F, Badreddine E, Bernard JP, Chi SN.
Manley PE, et al. Among authors: fauchet f.
Pediatr Blood Cancer. 2018 Sep;65(9):e27217. doi: 10.1002/pbc.27217. Epub 2018 May 11.
Pediatr Blood Cancer. 2018.
PMID: 29750396
Clinical Trial.